Posted in | News | Nanoenergy | Nanobusiness

Semprius to Accelerate Commercialization of Solar Photovoltaic Systems

Semprius, Inc., announced today that it has been selected by the National Renewable Energy Laboratory (NREL) to negotiate a $3 million subcontract funded by the U.S. Department of Energy (DOE) to commercialize its promising solar energy technology. Semprius is one of only four awardees for NREL's PV Technology Incubator Program, which aims to accelerate commercialization of solar photovoltaic systems.

The award recognizes Semprius' proprietary solar technology as one of the most promising and innovative approaches to making solar energy economically viable. Based near Research Triangle Park, the North Carolina company is commercializing novel Solar Module Arrays based on its patented micro-transfer printing technology.

Semprius Solar Module Arrays offer the benefits of low installed cost and high capacity factor which, combined, enable very low energy costs in sunny, dry climates. Their high efficiency, scalable design makes them applicable to a wide range of projects from distributed commercial and industrial to large scale utility installations.

“Semprius will use the subcontract to develop and then demonstrate our solar technology at the pilot plant scale. This is a critical next step on our path to full-scale manufacturing,” said Joe Carr, Semprius President and CEO. “We are honored to be selected from among the many submissions.”

Carr will give a presentation on the Semprius PV Module Array at the PHOTON 2nd PV Startup Conference, Feb 3, in San Francisco.

Semprius, Inc. is commercializing Solar Module Arrays based on patented micro-transfer printing, a highly efficient process for depositing high performance semiconductors onto any substrate, including glass, plastic and other materials. In addition to Solar Arrays, Semprius is licensing the technology for use in other applications such as LCD and OLED displays, MEMS and advanced disk drives.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.